Maastricht 2017 Meeting Highlights Registration Programme Overview Exhibition Virtual Exhibition Hotels Satellite Meetings Visa Letter Application Star Alliance Travel Discount

10 - 12 February 2017, MECC Maastricht,The Netherlands.

This Meeting has been awarded 15 CME credits.


Search Abstracts by author or title
(results will display both Free Papers & Poster)

TNF-α (−863) polymorphism and primary open angle glaucoma in Egyptians

Poster Details

First Author: A. Saeed EGYPT

Co Author(s): M. Nagy   U. Shalaby   W. Abdulwahab   S. Abdulrahman           

Abstract Details


The relationship between TNF-α and POAG has been extensively investigated worldwide at gene level with variable results in different populations. Polymorphisms in the promoter of the tumor necrosis factor alpha (TNF-α) gene have been reported to affect the transcription rate and the release of this cytokine. The most frequent and best studied are those at position –238 and –308. Another polymorphism, at the position –863 in the promoter region, has been studied less extensively. Our aim in this study was to investigate the possible association of −863C/A TNF-α gene promoter polymorphisms with POAG in an Egyptian group of subjects.


Ophthalmology department and Biochemistry & molecular pathology departments, Banha University, Egypt.


Genotypes of the TNF-α (−863) polymorphism were determined in 214 patients with POAG and 220 control subjects. Genotyping was performed by a polymerase chain reaction based restriction fragment length polymorphism (PCR-RFLP) assay.


The frequency of the TNF-α (−863) A allele in POAG group and control group were 3.07% and 5.22%, respectively. With no statistically significant difference between Genotype and allele frequencies of TNF-α −863C/A. (p=0.107) the carriers of the TNF-α (−863) A allele were 6.14% and 10.43% respectively. (p=0.099). CC genotype was 93.86% and 89.57%, respectively. (p=0.099)


Our data suggest that TNF-α (−863) polymorphism is not a major risk factor among Egyptian patients with POAG.

Financial Disclosure:


Back to Poster listing